Notably, Auxora — a selective Orai1 inhibitor — was tested in a phase 2 clinical study for patients with AP, SIRS, and hypoxemia; improved moderate AP in 36.5% of the patients; and enhanced the tolerance of solid food (51). Here, ORAI1 is linked to systemic inflammatory response syndrome.